

ASX Announcement

CORPORATE DIRECTORY

Chairman PAUL KRISTENSEN

Founder, Managing Director DAVID BUDGE

Business Development and Marketing Director NATHAN HENRY

Non-Executive Director MEL ASHTON

Non-Executive Director and Company Secretary MATHEW WHYTE

FAST FACTS

Issued Capital: 88.6m Quoted Options: 3.7m Unquoted Options: 2.8m Market Cap: \$35.5m Cash: \$6.2m

CONTACT DETAILS

U2/79 Bushland Ridge, Bibra Lake, WA AUSTRALIA 6163 t. +61 (0)8 9434 1934 auroralabs3d.com

ASX CODE: A3D ACN: 601 164 505

Aurora Labs signs collaboration agreement with the University of Western Australia (UWA) and Royal Perth Hospital (RPH) to 3D print medical implants

Highlights:

- Industry-led collaboration with two leading Western Australian entities to develop parameters, the 'how to' instructional guide for printing human medical implants using Aurora's Small Format Printer
- Application to Austrade to receive an Innovation Connections grant in relation to the Project

Aurora Labs Limited ("Aurora" or "the Company") (ASX:A3D), is pleased to announce that it has signed a binding term sheet with the University of Western Australia ("UWA") and Royal Perth Hospital ("RPH") in a collaboration agreement to develop 3D printing of titanium medical implants (the "Project").

The objective of the Project is to develop designs, specifications and parameters for the 3D printing of medical implants for use with humans using Aurora's S-Titanium Pro Small Format Printer. The parameters developed will be the 'how to' instructional guide for printing the human medical implants using an Aurora 3D printer.

This is an industry-led partnership and each party will contribute the appliances, goods, personnel and other resources to the Project. UWA will also provide a researcher to work on the Project.

The parties will apply to the Australian Trade and Investment Commission (Austrade) to receive an Innovation Connections grant in relation to the Project (Grant) for approx. A\$26,000. If the application for the grant is successful, all funds will be applied to costs of the Project.

David Budge, Managing Director of Aurora Labs, commented:

"This is an exciting collaboration and we are extremely pleased to be working with UWA and RPH, two leading entities in Australia. This partnership is a significant achievement for Aurora, it enhances our credibility, as well as certifying the potential application of additive manufacturing to the healthcare industry.

"It also demonstrates the advancement of additive manufacturing into multiple fields. The diversified use of titanium across a range of industries is well known, but in the medical field titanium is the most compatible metal with the human body. The suitability of Aurora's technology can service the need for on-demand medical implants that are customised to the patient."

Parties' role in the Project

• Aurora will provide UWA and RPH with one Printer (S-Titanium Pro) for their use in relation to the Project during the Project Term, free of charge. Aurora will also supply UWA and RPH with metallic consumable powders (consumables) for use with the Printer in relation to the Project, free of charge.

• RPH will provide appropriate designs of craniology plates for printing for the Project and consult on the cranioplasty application after printing.

During the Project, Aurora will make its maintenance and training staff available to UWA and/or RPH on an 'as needs' basis to provide reasonable advice and assistance regarding 3-dimensional metal printing matters and use of the Small Format Printer.

The Project will terminate 6 months after the award of the grant or completion of the research whichever is the earlier.

ABOUT AURORA LABS

Aurora Labs Limited ("the Company") (ASX: A3D), an industrial technology and innovation company that specialises in the development of 3D metal printers, powders, digital parts and their associated intellectual property.

Aurora Labs is listed on the Australian Securities Exchange (ASX: A3D)

To learn more about Aurora Labs, please visit: <u>www.auroralabs3d.com</u>

FORWARD LOOKING STATEMENTS

This announcement contains forward-looking statements which incorporate an element of uncertainty or risk, such as 'intends', 'may', 'could', 'believes', 'estimates', 'targets' or 'expects'. These statements are based on an evaluation of current economic and operating conditions, as well as assumptions regarding future events. These events are, as at the date of this announcement, expected to take place, but there cannot be any guarantee that such events will occur as anticipated or at all given that many of the events are outside Aurora's control.

Accordingly, Aurora and the directors cannot and do not give any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this announcement will actually occur.

For further information, please contact:

enquiries@auroralabs3D.com

t. +61 (0)8 9434 1934 e. enquiries@auroralabs3d.com ACN: 601 164 505 ASX Code: A3D auroralabs3d.com